A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
Latest Information Update: 26 May 2025
At a glance
- Drugs Baxdrostat (Primary) ; Dapagliflozin (Primary)
- Indications Hypertension; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms BaxDuo-Pacific
- Sponsors AstraZeneca
Most Recent Events
- 01 Apr 2025 Status changed from not yet recruiting to recruiting.
- 25 Dec 2024 New trial record